Strategic Vision: A Global Pharma Company
P&L Highlights - FY22
LUPIN
YOY
Amount in INR mn
FY2022
% of Sales
FY2021
% of Sales
Growth
Sales
161,928
Other operating income
2,127
Total revenue
164,055
100.0%
1.3%
101.3%
149,270
100.0%
8.5%
2,360
1.6%
-9.9%
151,630
101.6%
8.2%
Gross Profit
97,116
60.0%
95,648
64.1%
1.5%
(excl. other operating income)
EBITDA¹
23,073
14.2%
27,032
18.1%
-14.6%
PBT before exceptional item¹
12,135
7.5%
16,751
11.2%
Exceptional item 2/3
25,861
16.0%
0
0.0%
PBT after exceptional item
-13,726
-8.5%
16,751
11.2%
Profit after Tax
-15,097
-9.3%
12,266
8.2%
Profit/(Loss) for the period
-15,280
-9.4%
12,165
8.1%
1.
2.
In Q3 FY22, other expenses include the impact of one-time expenses of INR 1,932 mn related to residual Metformin returns from retail and consumers not identified
previously, and a provision for aged stock returns of Oseltamivir given lack of an active flu season for the past two years.
In Q2 FY2022 we had created a provision of INR 18,795 mn [including INR 375 mn towards litigation and settlement related expenses] under Glumetza class actions. The
amounts due to the two plantiffs group was settled in Q3. We had a small reversal on account of litigation expense in Q4 of INR 12 mn.
3.
Q2 FY2022 includes impairment expense of INR 7,077 mn for Solosec® IP.
11View entire presentation